SAB Bio Receives Fast Track Designation for SAB-142
SAB Biotherapeutics received FDA Fast Track designation for its T1D candidate SAB-142. The designation aims to expedite the review process for the registrational Phase 2b study.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed